Pmv Pharmaceuticals Inc (PMVP) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access PMVP Annual Balance Sheets →
Observing balance sheet movements over recent quarters helps explain how Pmv Pharmaceuticals Inc adapts its asset base and funding mix.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2026)
(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Assets
Cash & cash equivalent79.43
Marketable Securities, Current SH66.96
Cash & Short-term Investments145.00
Other Current Assets0.00
Prepaid Expense And Other Assets Current1.98
Total Current Assets81.41
Equipment/Property/Plant Net1.51
Long-term investments0.00
Other Assets, Noncurrent0.00
Operating Lease Right Of Use Asset0.28
Total Assets82.07
Liabilities
Accounts Payable, Current AC2.02
Accrued Liabilities, Current AC8.33
Other Liabilities, Current0.22
Total Current Liabilities10.57
Total Long-term Debt0.00
Other liabilities, Noncurrent0.00
OperatingLeaseLiabilityNoncurrent-
Operating Lease Liability Current0.29
Total Liabilities10.57
Stockholders' Equity
Additional Paid In Capital Common Stock554.16
Retained Earnings / Accumulated Deficit-482.58
Accumulated Other Comprehensive Income-0.08
Other Equity-0.08
Common Stockholder's Equity71.50
Total Stockholder's Equity71.50
Liabilities & Stockholder's Equity82.07
4 historic quarters locked

Sign in to unlock the full Pmv Pharmaceuticals Inc balance sheet history.

About Pmv Pharmaceuticals Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001193125-26-350448

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.